RxDoctor Payments Data

Theodore Affue, MD

Urology · El Centro, CANPI 1386674000

Payments from drug & device makers

$9,549in general payments, 2019–2025

Across 261 payments — averaging $36.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Astellas Pharma US Inc$1K
  • Teleflex LLC$1K
  • Bayer$845
  • Johnson & Johnson$567
  • Sumitomo Pharma America, Inc.$405
  • plus $2K from 24 others

What the payments were for

  • Speaking & faculty fees$3,00031%
  • Travel & lodging$2813%
  • Food & beverage$5,37356%
  • Education$8959%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,549 in reported general payments places this provider in the 70th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$835,408
Medicare patients
858
Services billed
14,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide184$2,436,338
NubeqaDarolutamide31$407,291
MyrbetriqMirabegron504$383,535
GemtesaVibegron400$342,676
Tamsulosin Hcl1,293$29,743
Mirabegron ErMirabegron34$17,699
Finasteride992$13,931
ErtapenemErtapenem Sodium19$13,908
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst441$7,282
Oxybutynin Chloride ErOxybutynin Chloride291$6,392
Dutasteride70$5,859
Testosterone Cypionate132$4,856
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav324$3,220
Bromocriptine Mesylate23$2,599
Bicalutamide69$2,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,167$2,819,874688 claims
BayerNubeqa$845$407,29131 claims
Sumitomo Pharma America, Inc.Gemtesa$405$342,676400 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,324 urology providers in California.

Other urology in El Centro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →